The Canadian government has given a startup, Optimi Health Corp., permission to export psychedelic substances to Australia for medicinal purposes. The substances include psilocybin, a magic mushroom extract, and MDMA, and the health department has approved their export.
This growing demand is not limited to the local magic mushrooms in Ontario. Countries worldwide are following Canada’s lead and beginning to examine and authorize the use of serotogenic compounds for medical uses.
Feel secure when you buy psychedelics online in Canada, and tap into your inherent capabilities through trusted sources.
[toc]Notable Highlights:
- Vancouver-based startup Optimi Health has received a drug establishment license to export magic mushroom pills to Australia.
- In Australia, licensed psychiatrists are allowed to use magic mushrooms to treat chronic depression.
- The treatment process involves three sessions over a period of five to eight weeks, with each session lasting around eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a Vancouver-based small-scale company, plans to use its certification to broaden the pharmaceutical market for psychedelic drugs and gain an early market entry advantage.
So far, seven companies have exported psilocybin, MDMA, or both, but only for clinical trials. A spokesperson from Canada’s health department could not confirm whether these exports were for regular patient use and opted not to reveal the companies, citing security reasons.
This accomplishment puts Optimi in a unique group of international suppliers, as the current market is primarily focused on clinical rather than recreational use.
What’s in the Pill?
Although the company has not disclosed the specific mushroom strain used in the pill, they have worked with various strains, including Albino Penis Envy.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, for the cultivation, testing, and extraction of its psychedelic mushrooms. This quaint town is home to approximately 3,000 inhabitants and is situated three hours east of Vancouver.
Australia and Psychedelic Mushrooms: A Complex Relationship
It’s projected that 1 in every 5 Australians between the ages of 16 and 85 may suffer a mental illness. PTSD (post-traumatic stress disorder) has the potential to affect 11% of Australians at some stage in their life, while anxiety disorders are common in 17% of the population.
There exists a broad spectrum of methods for addressing mental health issues, yet not all are effective for each person. Patients who don’t find relief in certain treatments often struggle to find a strategy that works for them, amplifying their vulnerability.
Understanding the Process
Australia has been a trailblazer in adopting psilocybin, allowing certified psychiatrists to use this regulated substance in the treatment of PTSD and depression resistant to traditional therapies.
In an unexpected decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic purposes. The TGA asserted that these substances are safe when used in a medically supervised setting for patients with severe mental disorders.
This change has had a profound impact on many mental health professionals and researchers. The administration of these substances will be carefully monitored; it’s not as simple as taking a pill and walking away.
The treatment protocol typically comprises three sessions over a period of five to eight weeks. Each session spans roughly eight hours, with the therapist accompanying the patient throughout the entire duration.
Canada’s Role in Advancing Psilocybin Research
Canada has risen as a key player in psilocybin research, significantly expanding our understanding of this substance. Health Canada, in collaboration with several institutions, is spearheading the investigation into the therapeutic capacity of psilocybin in alleviating various mental health conditions.
Research organizations are no longer required to categorize these substances as unlawful or rely on unregulated dispensaries or mushroom outlets. The government now permits certain institutions to grow mushrooms for research objectives.
The newfound availability of substances once deemed detrimental enables researchers to delve deeper into their potential benefits for a vast number of individuals.
A Recurrent Pattern
The potential of this discipline was initially acknowledged in the 1950s for tackling mental health complications and substance misuse, including alcohol dependency. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer were pioneers in this early exploration at the Weyburn The Saskatchewan Mental Hospital. This institution saw significant progress under the leadership of then-premier Tommy Douglas, who gave the medical community substantial freedom to investigate their medical hypotheses.
Dr. Osmond and Dr. Hoffer initiated investigations with LSD, mescaline, and peyote as potential alternatives to the harsh procedures of electroshock and lobotomy. Their research ventured into uncharted territories, with both advocating for medical professionals, nurses, and support staff to experiment with these substances.
Canadian Health Research Institutes
Through the Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research is funding three clinical trials to examine the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Lead Investigator | Project Budget |
| A randomized controlled trial | Psychological distress at end-of-life in patients with advanced-stage cancer | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms supporting psilocybin psychotherapy for treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial contrasting single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will enable a more thorough comprehension of the advantages of controlled substances. This has been made feasible by the Canadian Drugs and Substances Strategy (CDSS) implemented by the Government of Canada.
Further Psychedelic Research
Psychiatrists in Vancouver have initiated a phase III clinical trial of MDMA, commonly known as ecstasy, for the management of post-traumatic stress disorder (PTSD). The treatment includes three eight-hour sessions with MDMA, arranged one month apart, along with nine 90-minute sessions without the substance. This trial is considered historically meaningful as it marks the first clinical evaluation of an illicit
This marks the first significant scientific exploration of a psychedelic substance in over four decades.
A Deep Dive into Psilocybin
Psilocybin, a psychedelic compound occurring naturally in certain mushroom species, metabolizes into psilocin when ingested. Psilocin activates the serotonin 5-HT2a receptors on the cortical pyramidal cells in the brain, which are key processing sites.
The substance is currently under investigation by local authorities for its potential benefits in treating depression, anxiety, addiction, and end-of-life distress, by promoting introspection and spiritual enlightenment.
Why is it Effective Against Depression, PTSD, and More?
The active ingredient impacts various brain areas, which may prove beneficial for several mental disorders. The therapy has already been administered to numerous patients in Canada and Australia. The reported results show potential, with minor side effects such as temporary anxiety or increased blood pressure.
Neurobiological Impact
- Serotonin Receptor Activation: This compound acts as a partial agonist at serotonin receptors, especially the 5-HT2A subtype, crucial for mood regulation and emotional processing.
- Default Mode Network (DMN) Modulation: It reduces activity in the DMN, promoting introspection, decreasing rigid thought patterns, and enhancing emotional flexibility.
- Activation of Prefrontal and Limbic Regions: The antidepressant effects of the substance are due to its influence on the prefrontal and limbic brain regions, including the amygdala. In depression cases, individuals often show reduced responsiveness to emotional stimuli. The substance heightens the response to positive emotional stimuli in the right amygdala and normalizes the response to negative or neutral emotional stimuli.
Psychological and Emotional Impacts:
- Induction of Positive Mood States: It promotes feelings of euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience may allow individuals to safely address and process deep-seated emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Research from Johns Hopkins University and Imperial College Research from London suggests that magic mushrooms can facilitate enduring positive changes, such as increased well-being, greater life satisfaction, and spiritual growth.
What Products are Available at Your Local Magic Mushroom Stores?
Wondering how this substance might affect your mental health? Explore magic mushroom stores to find a product tailored to your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Boosts mood, stimulates creativity, and improves productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Enhances wellness and upgrades overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Induces clarity, fosters creativity, and sharpens focus. Contains a powerful mixture of clinical-grade adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy enhancements |
Worldwide Acceptance of Psilocybin
Canada is not the only country supporting the use of magic mushrooms for mental health treatment. Countries like Australia are also embracing these psychedelic substances to manage conditions like depression and PTSD. They are procuring top-quality psychedelic capsules from trusted sources. When used under suitable supervision, patients can significantly improve their life quality. Magic Mushrooms Ottawa Canada, a magic mushroom retailer, offers a variety of products, ranging from pills to LSD edibles.
Frequently Asked Questions
What are the similarities between psilocybin and MDMA?
Both psilocybin and MDMA have therapeutic potential by enhancing mental wellness. Psilocybin interacts with serotonin 2A receptors and is effective in treating depression and addiction.
Conversely, MDMA promotes empathy and is beneficial in PTSD treatment. It demonstrates potential in improving emotional processing and Despite being classified as a controlled substance, it has shown promising therapeutic results.
Is this treatment accessible to all Australians?
Not all Australians are eligible. In Australia, there is a requirement for individuals to undergo an assessment to ascertain their fitness for the substance use. This assessment takes into account factors such as pre-existing heart diseases, a history of psychosis, and so on. Only those patients who have not found relief from conventional treatments for disorders such as depression, anxiety, or PTSD can avail of this treatment.
What impact does Canada’s exportation of mushrooms have?
Canada is poised to take a leadership position in the psychedelics market, comparable to its role in the cannabis industry. This could result in an increase in companies producing high-quality products. Canada may thus become a leading player in the hallucinogen market, which could strengthen its economy and promote accessibility to treatments in other countries. It would also discourage other countries from obtaining their hallucinogens from unauthorized dispensaries or suppliers, thereby enhancing safety.
Articles That Might Interest You:
